Future of hepatocellular carcinoma incidence in the United States forecast through 2030

Journal of Clinical Oncology

Volumn 34, Issue 15, 2016, Pages 1787-1794

  Petrick, Jessica L ^a   Kelly, Scott P ^a   Altekruse, Sean F ^a   McGlynn, Katherine A ^a   Rosenberg, Philip S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ADULT; AGED; ARTICLE; ASIAN; BLACK PERSON; CANCER INCIDENCE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER REGISTRY; CAUCASIAN; COHORT ANALYSIS; ETHNIC DIFFERENCE; FEMALE; FORECASTING; GROUPS BY AGE; HEPATITIS C; HISPANIC; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PACIFIC ISLANDER; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE; UNITED STATES; CARCINOMA, HEPATOCELLULAR; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; TIME FACTORS; UNITED STATES;

EID: 84969568007     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.7412     Document Type: Article

References (47)

1. Altekruse SF, Devesa SS, Dickie LA, et al: Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J Registry Manag 38: 201-205, 2011
2. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273.e1, 2012
3. Smith BD, Morgan RL, Beckett GA, et al: Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 61:1-32, 2012
4. King DE, Matheson E, Chirina S, et al: The status of baby boomers' health in the United States: The healthiest generation? JAMA Intern Med 173:385-386, 2013
5. McGlynn KA, Petrick JL, London WT: Global epidemiology of hepatocellular carcinoma: An emphasis on demographic and regional variability. Clin Liver Dis 19:223-238, 2015
6. Ortman J, Velkoff V, Hogan H: An Aging Nation: The Older Population in the United States. Current Population Reports, US Census Bureau, 2014. www.census.gov/prod/2014pubs/p25-1140.pdf
7. Greten TF, Papendorf F, Bleck JS, et al: Survival rate in patients with hepatocellular carcinoma: A retrospective analysis of 389 patients. Br J Cancer 92:1862-1868, 2005
8. Surveillance, Epidemiology, and End Results (SEER) Program. SEER∗Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2014 Sub (2000- 2012) , Katrina/Rita Population Adjustment. - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.
9. International Classification of Diseases for Oncology (ed 3). Geneva, World Health Organization, 2000
10. Surveillance, Epidemiology, and End Results (SEER) Program. SEER∗Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2014 Sub (1975- 2012) , Katrina/Rita Population Adjustment. - Linked To County Attributes - Total U.S., 1969-2013 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission.
11. US Census Bureau: 2012 National Population Projections, 2012. www.census.gov/population/projections/data/national/2012.html
12. Rosenberg PS, Barker KA, Anderson WF: Estrogen receptor status and the future burden of invasive and in situ breast cancers in the United States. J Natl Cancer Inst 107:djv159, 2015
13. Rosenberg PS, Check DP, Anderson WF: A web tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 23:2296-2302, 2014
14. Kim HJ, Fay MP, Feuer EJ, et al: Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335-351, 2000
15. The MathWorks I. MATLAB: The Language of Technical Computing. 2014b ed. Natick, MA: The MathWorks, Inc., 2014
16. Weir HK, Thompson TD, Soman A, et al: The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer 121: 1827-1837, 2015
17. Rahib L, Smith BD, Aizenberg R, et al: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913-2921, 2014
18. Smith BD, Smith GL, Hurria A, et al: Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 27: 2758-2765, 2009
19. Altekruse SF, Henley SJ, Cucinelli JE, et al: Changing hepatocellular carcinoma incidence and liver cancermortality rates in the United States. Am J Gastroenterol 109:542-553, 2014
20. Schweitzer A, Horn J, Mikolajczyk RT, et al: Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 386: 1546-1555, 2015
21. World Health Organization: WHO vaccinepreventable disease monitoring system, 2015 global summary. World Health Organization, 2015. http://apps.who.int/immunization-monitoring/globalsummary/timeseries/tswucoveragehepb3.html
22. Grieco EM, Acosta YD, de la Cruz GP, et al: The Foreign-Born Population in the United States: 2010. American Community Survey Reports. 2012. www.census.gov/prod/2012pubs/acs-19.pdf
23. Welzel TM, Graubard BI, Quraishi S, et al: Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 108:1314-1321, 2013
24. Chhatwal J, Kanwal F, Roberts MS, et al: Costeffectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 162:397-406, 2015
25. Drenth JP: HCV treatment-no more room for interferonologists? N Engl J Med 368:1931-1932, 2013
26. U.S. Food and Drug Administration. FDA approves Sovaldi for chronic hepatitis C [press release]. Silver Spring, MD: U.S. Food and Drug Administration; 6 December 2013. www.fda.gov/newsevents/newsroom/pressannouncements/ucm377888.htm
27. U.S. Food and Drug Administration. FDA approves new treatment for hepatitis C virus [press release]. Silver Spring, MD: U.S. Food and Drug Administration; 22 November 2013. www.fda.gov/newsevents/newsroom/pressannouncements/ucm376449.htm
28. U.S. Food and Drug Administration. FDA approves first combination pill to treat hepatitis C [press release]. Silver Spring, MD: U.S. Food and Drug Administration; 10 October 2014. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm
29. Lawitz E, Mangia A, Wyles D, et al: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368:1878-1887, 2013
30. Afdhal N, Reddy KR, Nelson DR, et al: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483-1493, 2014
31. Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. www.hcvguidelines.org/
32. Sussman NL, Remien CH, Kanwal F: The end of hepatitis C. Clin Gastroenterol Hepatol 12:533-536, 2014
33. Hoofnagle JH, Sherker AH: Therapy for hepatitis C-the costs of success. N Engl J Med 370: 1552-1553, 2014
34. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among adults: United States, 2011-2012. NCHS data brief, no 131. Hyattsville, MD: National Center for Health Statistics, 2013
35. Finkelstein EA, Khavjou OA, Thompson H, et al: Obesity and severe obesity forecasts through 2030. Am J Prev Med 42:563-570, 2012
36. NAACCR Race and Ethnicity Work Group (ed): NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]. Springfield, IL, North American Association of Central Cancer Registries, 2010
37. Boscoe FP, Schymura MJ, Zhang X, et al: Heuristic algorithms for assigning Hispanic ethnicity. PLoS One 8:e55689, 2013
38. Stern MC, Zhang J, Lee E, et al: Disparities in colorectal cancer incidence among Latino subpopulations in California defined by country of origin. Cancer Causes Control 27:147-155, 2016
39. Cokkinides VE, Bandi P, Siegel RL, et al: Cancer-related risk factors and preventive measures in US Hispanics/Latinos. CA Cancer J Clin 62: 353-363, 2012
40. Thomas DB, Karagas MR: Cancer in first and second generation Americans. Cancer Res 47: 5771-5776, 1987
41. Clegg LX, Feuer EJ, Midthune DN, et al: Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst 94:1537-1545, 2002
42. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2012. http://seer.cancer.gov/csr/1975-2012/
43. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27:1485-1491, 2009
44. Howlader N, Ries LA, Stinchcomb DG, et al: The impact of underreported Veterans Affairs data on national cancer statistics: analysis using populationbased SEER registries. J Natl Cancer Inst 101: 533-536, 2009
45. Ulahannan SV, Duffy AG, McNeel TS, et al: Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology 60:1637-1644, 2014
46. Altekruse SF, Petrick JL, Rolin AI, et al: Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States. PLoS One 10: e0120574, 2015
47. Simard EP, Ward EM, Siegel R, et al: Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62:118-128, 2012